CABG Underused in Diabetes With Multivessel Disease

This article originally appeared here.
Share this content:
CABG Underused in Diabetes With Multivessel Disease
CABG Underused in Diabetes With Multivessel Disease

MONDAY, May 16, 2016 (HealthDay News) -- About one-third of patients with diabetes mellitus and multivessel coronary artery disease presenting with non-ST-segment elevation myocardial infarction undergo coronary artery bypass graft (CABG) and more undergo percutaneous coronary intervention (PCI), according to a study published online May 10 in Circulation: Cardiovascular Quality and Outcomes.

Ambarish Pandey, M.D., from the UT Southwestern Medical Center in Dallas, and colleagues compared in-hospital use of different revascularization strategies in patients with diabetes mellitus with non-ST-segment elevation myocardial infarction with multivessel coronary artery disease between July 2008 and December 2014. Data were included for 29,769 patients from 539 hospitals, of whom 36.4, 46.2, and 17.3 percent were treated with CABG, PCI, and without revascularization, respectively.

The researchers found that over the study period there was an increase in the overall use of revascularization; the proportion undergoing PCI increased (45 to 48.9 percent; Ptrend = 0.0002), while there was no change in the proportion undergoing CABG (36.1 to 34.7 percent; Ptrend = 0.88). Participating hospitals had significant variability in the use of PCI (22 to 100 percent) and CABG (0 to 78 percent) (both P < 0.0001). Several patient-level characteristics were significantly associated with use of PCI versus CABG.

"Future studies focused on risk perception of patients and operator-level practice patterns are needed to better understand the drivers of the observed variability in revascularization practice in this patient population," the authors write.

Several authors disclosed financial ties to the pharmaceutical and medical device industries.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves Zejula for Certain Female Cancers

FDA Approves Zejula for Certain Female Cancers

PARP inhibitor may help fight tumors affecting the ovaries, fallopian tubes, or peritoneum

USPSTF: Evidence Lacking for Celiac Dz Screen in Asymptomatic

USPSTF: Evidence Lacking for Celiac Dz Screen in ...

Insufficient evidence for weighing benefits, harms of screening for celiac disease in asymptomatic

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Equivalent disease-free survival at 4.5 years for stage I endometrial cancer with TAH, TLH

is free, fast, and customized just for you!

Already a member?

Sign In Now »